Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 4/20 | 0.54 |
| ▸ | KIF11 | P52732 | 5/20 | 0.53 |
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21639223 | 1.00 | MDM2 (0.54) | MDM2KIF11MDM4TP53SLC17A5 | |
| SCHEMBL29400885 | 1.00 | MDM2 (0.54) | MDM2KIF11MDM4TP53SLC17A5 | |
| SCHEMBL29460482 | 1.00 | MDM2 (0.54) | MDM2KIF11MDM4TP53SLC17A5 | |
| SCHEMBL29395463 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL29560536 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL1738641 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL5998507 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL3436122 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL29503847 | 0.92 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL12127262 | 0.92 | KIF11 (0.51) | MDM2KIF11MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137003-A | Method for chemically synthesizing glycosylated insulin | 中国医学科学院药物研究所 | 2025-06-13 | — | — | CN | claimed |
| CN-113801196-B | Preparation method of procalcitonin | 深圳翰宇药业股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-118290538-A | GABA with analgesic activityAReceptor targeting peptide DZ2 and synthesis method and application thereof | 河北医科大学 | 2024-07-05 | — | — | CN | claimed |
| CN-113929763-B | Method for preparing semenopeptide by using soluble label as carrier | 申联生物医药（上海）股份有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-115894630-A | Preparation method of linaclotide | 四川轻化工大学 | 2023-04-04 | — | — | CN | claimed |
| CN-114044813-B | Preparation and purification method of procatide | 浙江湃肽生物有限公司南京分公司 | 2022-04-15 | — | — | CN | claimed |
| CN-113956333-B | Synthesis and purification method of linaclotide | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-110609078-B | Method for detecting protein phosphorylation and acetylglucosamine saccharification correlation effect | 南京谱利健生物技术有限公司 | 2022-03-11 | — | — | CN | claimed |
| CN-114133455-A | Synthesis method of desmopressin acetate dimer impurity | 深圳翰宇药业股份有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-114044813-A | Preparation and purification method of procatide | 浙江湃肽生物有限公司南京分公司 | 2022-02-15 | — | — | CN | claimed |
| EP-4745151-A1 | FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | UNIVERSITAET WIEN (AT) | 2026-04-30 | — | — | US | disclosed |
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2026-04-30 | — | — | US | disclosed |
| US-12577274-B2 | Manufacture of glucagon peptides | BACHEM HOLDING AG (CH) | 2026-03-17 | — | — | US | disclosed |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2026-01-20 | — | — | US | disclosed |
| US-7964729-B2 | Sox-based kinase sensor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-06-21 | — | — | US | disclosed |
| WO-2008082715-A2 | SOX-BASED KINASE SENSOR | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080050761-A1 | Sox-based kinase sensor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2008-02-28 | — | — | US | disclosed |
| US-20080050761-A1 | Sox-based kinase sensor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2008-02-28 | — | — | US | disclosed |
| WO-2005108353-A2 | COMPOUNDS FOR TREATING NEUROLOGIC DISEASES, OTOLOGIC DISEASES, OR OPHTHALMOLOGIC DISEASES AND METHODS OF USE THEREOF | CEPTOR CORPORATION (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115268-A1 | Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens | SCN8A, SCN9A, VIP | MDM2 4474/4885KIF11 2147/4885MDM4 4004/4885 |
| US-20080050761-A1 | Sox-based kinase sensor | SOX18, HIPK1, HIPK3 | MDM2 1622/4885KIF11 3044/4885MDM4 1262/4885 |
| US-12577274-B2 | Manufacture of glucagon peptides | IAPP, GLP1R, GCG | MDM2 4043/4885KIF11 4019/4885MDM4 4113/4885 |
| US-12527853-B2 | Heat-stable enterotoxins mutants as antidiarrheal vaccine antigens | VIP, MLEC, SEC16A | MDM2 3421/4885KIF11 2066/4885MDM4 2800/4885 |
| US-20260116922-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | OXTR, CRH, TRHR | MDM2 3967/4885KIF11 2924/4885MDM4 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.